Li et al., 2012 - Google Patents
Gr‐1+ CD11b+ cells are responsible for tumor promoting effect of TGF‐β in breast cancer progressionLi et al., 2012
View HTML- Document ID
- 18120974225245877652
- Author
- Li Z
- Pang Y
- Gara S
- Achyut B
- Heger C
- Goldsmith P
- Lonning S
- Yang L
- Publication year
- Publication venue
- International journal of cancer
External Links
Snippet
One great challenge in our understanding of TGF‐β cancer biology and the successful application of TGF‐β‐targeted therapy is that TGF‐β works as both a tumor suppressor and a tumor promoter. The underlying mechanisms for its functional change remain to be …
- 101710006572 ITGAM 0 title abstract description 154
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Gr‐1+ CD11b+ cells are responsible for tumor promoting effect of TGF‐β in breast cancer progression | |
| DeVorkin et al. | Autophagy regulation of metabolism is required for CD8+ T cell anti-tumor immunity | |
| Huang et al. | Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity | |
| Dosset et al. | PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer | |
| Wu et al. | IL1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer | |
| Galdiero et al. | Tumor associated macrophages and neutrophils in tumor progression | |
| Shiraishi et al. | CD163 is required for protumoral activation of macrophages in human and murine sarcoma | |
| Ding et al. | CXCL9: evidence and contradictions for its role in tumor progression | |
| Cascio et al. | Cancer-associated MSC drive tumor immune exclusion and resistance to immunotherapy, which can be overcome by Hedgehog inhibition | |
| Koyama et al. | STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment | |
| Affara et al. | B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas | |
| Cao et al. | BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity | |
| Yuan et al. | Tumor‐derived CXCL1 promotes lung cancer growth via recruitment of tumor‐associated neutrophils | |
| Brockwell et al. | Neoadjuvant interferons: Critical for effective PD-1–based Immunotherapy in TNBC | |
| Alexandrakis et al. | Relationship between circulating BAFF serum levels with proliferating markers in patients with multiple myeloma | |
| Yan et al. | CCL9 induced by TGFβ signaling in myeloid cells enhances tumor cell survival in the premetastatic organ | |
| Holmgaard et al. | Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy | |
| Kee et al. | CXCL16 suppresses liver metastasis of colorectal cancer by promoting TNF-α-induced apoptosis by tumor-associated macrophages | |
| McMichael et al. | A phase I/II trial of cetuximab in combination with interleukin-12 administered to patients with unresectable primary or recurrent head and neck squamous cell carcinoma | |
| Cook et al. | Granulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation | |
| Tucci et al. | Immature dendritic cells in multiple myeloma are prone to osteoclast‐like differentiation through interleukin‐17 A stimulation | |
| Bazzichetto et al. | From genetic alterations to tumor microenvironment: the Ariadne’s string in pancreatic cancer | |
| Llosa et al. | Interleukin-17 and type 17 helper T cells in cancer management and research | |
| Zhao et al. | Activation of epidermal growth factor receptor in macrophages mediates feedback inhibition of M2 polarization and gastrointestinal tumor cell growth | |
| Leanderson et al. | S100A9 as a pharmacological target molecule in inflammation and cancer |